Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Simbioflora
- Development stage
- Unknown
- Lead developer
- Farmoquímica
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Simbioflora is a synbiotic supplement composed of a proprietary blend of probiotic bacteria, including species of *Bifidobacterium* and *Lactobacillus*, combined with the prebiotic fiber fructooligosaccharides (FOS). It is primarily used to modulate the gastrointestinal microbiota, particularly in patients undergoing cancer treatments such as surgery or chemoradiotherapy. By promoting the growth of beneficial bacteria and inhibiting pathogens, Simbioflora aims to reduce systemic inflammatory markers like C-reactive protein (CRP) and interleukin-6 (IL-6), improve gut barrier function, and decrease the incidence of postoperative infectious complications. The product is developed and marketed by the Brazilian pharmaceutical company Farmoquimica (FQM).
- Brand names
- Simbioflora
- Other names
- synbioticprobiotic + prebiotic
Beyond the preview
Go deeper on Simbioflora.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Simbioflora.